Trial Profile

A randomized, double-blind, placebo-controlled, multi-center phase 3 registrational study of larsucosterol in alcohol-associated hepatitis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larsucosterol (Primary) ; Methylprednisolone
Indications Alcoholic hepatitis
Focus Registrational; Therapeutic Use
Sponsors DURECT Corporation

Most Recent Events

26 Mar 2025 According to a DURECT Corporation media release, topline results expected within two years of trial initiation.
26 Mar 2025 According to a DURECT Corporation media release, data from AHFIRM study were presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH).
28 Jan 2025 event According to a DURECT Corporation media release, the company plan to initiate the trial in 2025, pending funding.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com